Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Ginkgo flavonglycosides, derived from the leaves of Ginkgo biloba, have been studied for their potential to support cognitive function and delay the progression of senility, particularly in the context of age-related cognitive decline and mild to moderate dementia (including Alzheimer’s disease). The scientific basis for their use lies in their purported neuroprotective effects, antioxidative properties, and ability to improve cerebral blood flow. Several randomized controlled trials and meta-analyses (e.g., Yang et al., 2016, Cochrane Review 2020) indicate that standardized Ginkgo biloba extracts (typically EGb 761, containing 24% flavonglycosides) can lead to modest improvements in cognitive function, activities of daily living, and global clinical impression in patients with dementia compared to placebo.

However, the effect sizes are generally small and the quality of evidence varies, with some studies showing no significant benefit. Guidelines from organizations such as the American Academy of Neurology (AAN) and the National Institute for Health and Care Excellence (NICE) do not currently recommend Ginkgo biloba as a first-line treatment, but acknowledge that some evidence exists for its symptomatic benefit. Adverse effects are generally mild but may include gastrointestinal symptoms or increased bleeding risk. In summary, there is moderate scientific evidence supporting the use of Ginkgo flavonglycosides for cognitive decline in senility, but results are mixed and its use should be considered adjunctive rather than primary therapy.

More about Ginkgo Flavonglycosides
More about Senility

Other ingredients used for Senility

Other health conditions supported by Ginkgo Flavonglycosides

Products containing Ginkgo Flavonglycosides